Clinical characteristics and outcomes of previously untreated patients with adult onset T-acute lymphoblastic leukemia and T-lymphoblastic lymphoma with hyper-CVAD based regimens

被引：10
|
作者：
Jain, Preetesh [1 ]
Kantarjian, Hagop [1 ]
Jain, Nitin [1 ]
Short, Nicholas J. [1 ]
Yin, Cameron C. [2 ]
Kanagal-Shamanna, Rashmi [2 ]
Khoury, Joseph [2 ]
Konopleva, Marina [1 ]
Sasaki, Koji [1 ]
Kadia, Tapan M. [1 ]
Garris, Rebecca [1 ]
Pierce, Sherry [1 ]
Estrov, Zeev [1 ]
Wierda, William [1 ]
Cortes, Jorge [1 ]
O'Brien, Susan [3 ]
Ravandi, Farhad [1 ]
Jabbour, Elias [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Hematopathol, Houston, TX 77030 USA
[3] Univ Calif Irvine, Chao Family Comprehens Canc Ctr, Orange, CA 92668 USA
来源：
AMERICAN JOURNAL OF HEMATOLOGY | 2017年 / 92卷 / 10期
关键词：
THERAPY;
D O I：
10.1002/ajh.24833
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：E595 / E597
页数：4
相关论文
共 50 条
  • [21] Poor Outcomes with Hyper CVAD Induction for T-Cell Lymphoblastic Leukemia/Lymphoma
    Kota, Vamsi K.
    Hathaway, Amanda Redden
    Shah, Bijal D.
    Peker, Deniz
    Zhang, Ling
    Jaye, David L.
    Arellano, Martha
    Khoury, H. Jean
    Jillella, Anand P.
    Winton, Elliott F.
    Heffner, Leonard T., Jr.
    Borate, Uma
    BLOOD, 2015, 126 (23)
  • [22] Phase II study of hyper-CVAD followed by nelarabine consolidation in newly diagnosed patients with T cell acute lymphoblastic leukemia/lymphoblastic lymphoma (ALL/LL).
    Vigil, C. E.
    Kantarjian, H.
    Thomas, D. A.
    O'Brien, S. M.
    Kashani, F. Ravandi
    Koller, C. A.
    Burger, J. A.
    Garris, R. S.
    Baccus, M. D.
    Faderl, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [23] Clinical experience with frontline Hyper-CVAD-based regimens, including Hyper-CVAD plus ponatinib, in patients with acute lymphoblastic leukemia treated at a comprehensive cancer center
    Othman, Tamer
    Moskoff, Benjamin N.
    Ho, Gwendolyn
    Tenold, Matthew E.
    Azenkot, Tali
    Krackeler, Margaret L.
    Fisch, Samantha C.
    Potter, Laura A.
    Kaesberg, Paul R.
    Welborn, Jeanna L.
    Wun, Ted
    Esteghamat, Naseem S.
    Hoeg, Rasmus T.
    Rosenberg, Aaron S.
    Abedi, Mehrdad
    Tuscano, Joseph M.
    Jonas, Brian A.
    LEUKEMIA RESEARCH, 2022, 119
  • [24] Comparison of two induction regimens, high dose cytarabine/mitoxantrone vs hyper-CVAD, for adult acute lymphoblastic leukemia/lymphoma.
    Jeong, WD
    Liu, DL
    Katragadda, S
    Shi, QH
    Ahmed, T
    Seiter, K
    BLOOD, 2005, 106 (11) : 226B - 226B
  • [25] Hyper-CVAD program in Burkitt's-type adult acute lymphoblastic leukemia
    Thomas, DA
    Cortes, J
    O'Brien, S
    Pierce, S
    Faderl, S
    Albitar, M
    Hagemeister, FB
    Cabanillas, FF
    Murphy, S
    Keating, MJ
    Kantarjian, H
    JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (08) : 2461 - 2470
  • [26] Remission induction chemotherapy with Hyper CVAD including idarubicin for previously untreated adult acute lymphoblastic leukemia.
    Cheong, JW
    Lee, ST
    Hahn, JS
    Ko, YW
    Min, YH
    BLOOD, 2001, 98 (11) : 210B - 210B
  • [27] Incorporation of Nelarabine (NEL), Pegylated Asparaginase (PEG) and Venetoclax (VEN) in the Frontline Therapy of Adult Patients with T-Acute Lymphoblastic Leukemia/T-Lymphoblastic Lymphoma (T-ALL/LBL)
    Babakhanlou, Rodrick
    Kantarjian, Hagop
    Jabbour, Elias
    Borthakur, Gautam
    Konopleva, Marina
    Wierda, William G.
    Burger, Jan A.
    Issa, Ghayas C.
    Maiti, Abhishek
    Balkin, Hayley
    Kelly, Mary
    Garris, Rebecca
    Ferrajoli, Alessandra
    Garcia-Manero, Guillermo
    Alvarado, Yesid
    Short, Nicholas
    Jain, Nitin
    Ravandi, Farhad
    BLOOD, 2022, 140 : 11671 - 11673
  • [28] Nelarabine, etoposide, and cyclophosphamide in relapsed pediatric T-acute lymphoblastic leukemia and T-lymphoblastic lymphoma (study T2008-002 NECTAR)
    Whitlock, James A.
    Malvar, Jemily
    Dalla-Pozza, Luciano
    Goldberg, John M.
    Silverman, Lewis B.
    Ziegler, David S.
    Attarbaschi, Andishe
    Brown, Patrick A.
    Gardner, Rebecca A.
    Gaynon, Paul S.
    Hutchinson, Raymond
    Huynh, Van T.
    Jeha, Sima
    Marcus, Leigh
    Messinger, Yoav
    Schultz, Kirk R.
    Cassar, Jeannette
    Locatelli, Franco
    Zwaan, C. Michel
    Wood, Brent L.
    Sposto, Richard
    Gore, Lia
    PEDIATRIC BLOOD & CANCER, 2022, 69 (11)
  • [29] Treatment of young adults with Philadelphia-negative acute lymphoblastic leukemia and lymphoblastic lymphoma: Hyper-CVAD vs. pediatric-inspired regimens
    Siegel, Stuart E.
    Advani, Anjali
    Seibel, Nita
    Muffly, Lori
    Stock, Wendy
    Luger, Selina
    Shah, Bijal
    DeAngelo, Daniel J.
    Freyer, David R.
    Douer, Dan
    Johnson, Rebecca H.
    Hayes-Lattin, Brandon
    Lewis, Mark
    Jaboin, Jerry J.
    Coccia, Peter F.
    Bleyer, Archie
    AMERICAN JOURNAL OF HEMATOLOGY, 2018, 93 (10) : 1254 - 1266
  • [30] Outcome for Adolescents and Young Adults (AYA) with the Hyper-CVAD (with or without Rituximab) Regimens for De Novo Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma.
    Thomas, Deborah A.
    Rytting, Michael
    O'Brien, Susan
    Faderl, Stefan
    Wierda, William G.
    Franklin, Anna
    Garris, Rebecca
    Ravandi, Farhad
    Cortes, Jorge
    Kantarjian, Hagop M.
    BLOOD, 2009, 114 (22) : 1199 - 1199
12345